Investor Spotlight: GreyBird Ventures Heads to RESI to Source New Diagnostic Technologies

2 Aug

By Claire Jeong, Senior Research Analyst, LSN

claire

It’s challenging to pitch a diagnostics opportunity to investors, and many entrepreneurs in the field feel that it’s hard to uncover investors who have a strong focus on the field.  At RESI Boston on September 6th, two panel sessions will focus on the difficulties and the possibilities for new technologies that will guide patient care in the future.

Tom Miller, Managing Director of GreyBird Ventures, will be the moderator of the RESI panel on Personalized Medicine.  As his firm has a focus on diagnostic technologies, LSN is delighted to have Tom as the leader of this 50-minute discussion at RESI where the future of personalized care will be in the spotlight.  We asked Tom about his goals for the event.

What will RESI attendees learn from you?

As, unlike most healthcare VCs, we are focused on technologies for diagnosis, we can give solid advice on that particular segment.  Diagnostic technologies have many of the same requirements as pharmaceuticals in terms of clinical trials needs and the importance of solid clinical data but very different boundary conditions for capital efficiency and exit expectations.

What makes you excited to attend RESI?

It is a very efficient use of time.  We get to see a large number of companies that exactly fit our investment strategy and focus in the speed-dating format.  And the match-making software allows us to weed out those companies that would not be a fit making sure that both sides do not waste time.  I also get to meet like-minded investors as we are always seeking best practices from which we can learn.

Investing in Personalized Medicine
Thursday, September 6th, 2018
3:00 – 3:50 PM

This panel will discuss current trends in personalized medicine.  Topics may include:

  • How investors assess personalized medicine technologies and applications in diagnostics, drug discovery and treatment plans
  • Which indications investors believe are showing the most promise – genetic disorders, orphan diseases, oncology, etc.
  • Investing in individualized treatments (such as CAR-T) and the scalability challenges of autologous vs allogeneic/xenogeneic off-the-shelf treatments
  • The regulatory challenges some of these technologies face, whether to ensure individual privacy from genomics databanks or to prevent potential harmful side effects from therapeutics such as CRISPR technologies

Personalized medicine has proven to produce more effective treatments in multiple indications by tailoring medical treatment to the individual and their disease. Additionally, early detection of disease has improved outcomes for many patients. Panelists will discuss where the field is heading and what unique challenges companies in this area will face.

Tom Miller

After receiving a degree in Nuclear Engineering from the University of Massachusetts at Lowell, Tom studied Medical Physics at the Harvard/MIT Health Sciences and Technology joint program graduating with a Masters degree in 1982.  During his academic career he worked at Los Alamos, the Swiss Institute for Nuclear Research (now the Paul Scherer Institute), Brookhaven National Laboratory, and the Massachusetts General Hospital as a research associate in radiation biophysics.

Tom then joined Siemens Medical Systems where, after 9 years, he became the first non-German CEO of a German factory and business unit.  He left Siemens after 15 years to become CEO of the global medical operations of Carl Zeiss.  Completing a successful turnaround, he joined Analogic Corporation as CEO.  After three years and a doubling of the stock price, Tom left to become CEO of LightLab Imaging, a start-up that he helped to establish.  Completing a profitable sale of LightLab, Tom re-joined Siemens eventually serving as a member of the operating board of Siemens Healthcare and the CEO of Customer Solutions Division, responsible for 26,000 employees in over 130 countries.  Tom co-founded GreyBird in mid-2013 with an investment focus on technologies enabling precision medicine diagnosis.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: